Trovagene Inc., of San Diego, said the first patient completed the first cycle of dosing with PCM-075, an oral PLK1-selective adenosine triphosphate competitive inhibitor, in combination with low-dose cytarabine in its phase Ib/II trial of patients with acute myeloid leukemia (AML). The open-label study will test PCM-075 in combination with standard-of-care chemotherapy in AML patients who are ineligible for intensive induction therapy or whose disease is relapsed or refractory.